Alkaloida's Sales Stagnate

2 June 1996

The Hungarian drugs producer Alkaloida is projecting sales for the current year of 8.3 billion forint ($54.7 million), similar to those in 1995, reports MTI Econews. The company is forecasting gross profits of 123.3 million forint, rising 44%.

Last year's net sales increased by 200 million forint as compared with 1994, with a rise in production volume of drugs and intermediaries. However, its debts grew to 5 billion forint last year from 3.5 billion forint in 1994.

In 1995, Alkaloida introduced 15 new products and built a waste incinerator worth 520 million forint.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight